<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41989">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02061124</url>
  </required_header>
  <id_info>
    <org_study_id>H-2-2013-148</org_study_id>
    <nct_id>NCT02061124</nct_id>
  </id_info>
  <brief_title>Effect of Bile Acid Sequestration on Postprandial GLP-1 Secretion, Glucose Homeostasis and Gut Microbiota</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <authority>Denmark: The Regional Committee on Biomedical Research Ethics</authority>
    <authority>Denmark: National Board of Health</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Accumulating evidence suggests that bile acids and bacteria in our intestines may constitute
      essential components in the complex mechanisms regulating gut hormone secretion and glucose
      homeostasis. At the same time, bile acids and gut bacteria are interdependent. Thus, it is
      likely that modification of the enterohepatic circulation of bile acids can lead to changes
      in gut hormone secretion or gut bacteria composition and consequently affect glucose
      homeostasis.

      The current study is a human interventional study with 7-day ingestion of a bile acid
      sequestrant or placebo, preceded and followed by meal tests and faecal sampling. The aim is
      to examine how (and if) bile acid sequestration can influence postprandial glucagon-like
      peptide-1 (GLP-1) secretion, gut microbiota and glucose homeostasis in patients with type 2
      diabetes and healthy individuals. As a tool to sequester bile acids we will use sevelamer, a
      phosphate binding resin used in the treatment of hyperphosphataemia in adult patients with
      chronic kidney disease. Surprisingly, sevelamer was recently shown to improve glycaemic
      control in patients with chronic kidney disease and type 2 diabetes.

      The investigators hypothesize that higher luminal concentrations of bile acids in the distal
      gut will elicit changes in the postprandial gut hormone secretion and gut bacteria
      composition. The current study will help to clarify this hypothesis and improve our general
      understanding of the association between bile acid circulation and signalling, gut hormone
      secretion, gut bacteria and glucose metabolism.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Incremental and total area under the Concentration-Time Curve (AUC 0-240 min)</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 45, 60, 90, 120, 180, 240 min on study days 1 and 7 (meal tests start at 0 min)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Postprandial responses of glucagon-like peptide-1 (GLP-1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incremental and total area under the Concentration-Time Curve (AUC 0-240 min)</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 45, 60, 90, 120, 180, 240 min on study days 1 and 7 (meal tests start at 0 min)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Postprandial responses of various other gut hormones</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood analysis</measure>
    <time_frame>Fasting status on study days 1 and 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Lipids</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood analysis</measure>
    <time_frame>Fasting status on study days 1 and 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Inflammatory and metabolic markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Faecal samples</measure>
    <time_frame>Prior to study days 1 and 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gut microbiota composition</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood analysis of paracetamol</measure>
    <time_frame>-30 min to 240 min (ingestion of meal at 0 min) on study days 1 and 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of gastric emptying</description>
  </other_outcome>
  <other_outcome>
    <measure>Bodyweight</measure>
    <time_frame>Fasting state on study days 1 and 7</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Indirect calorimetry</measure>
    <time_frame>-30 min to 240 min (ingestion of meal at 0 min) on study days 1 and 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Basal metabolic rate</description>
  </other_outcome>
  <other_outcome>
    <measure>Ultrasound measurements</measure>
    <time_frame>-30 min to 240 min (ingestion of meal at 0 min) on study days 1 and 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gall bladder volume</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual analog scale score</measure>
    <time_frame>-30 min to 240 min (ingestion of meal at 0 min) on study days 1 and 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Appetite</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>T2DM, sevelamer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with type 2 diabetes treated with sevelamer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with type 2 diabetes treated with placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects, sevelamer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy subjects treated with sevelamer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy subjects treated with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer 1600 mg TID for 7 days</intervention_name>
    <arm_group_label>T2DM, sevelamer</arm_group_label>
    <arm_group_label>Healthy subjects, sevelamer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 1600 mg TID for 7 days</intervention_name>
    <arm_group_label>T2DM, placebo</arm_group_label>
    <arm_group_label>Healthy subjects, placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Both groups

          -  Caucasian ethnicity

          -  Normal haemoglobin

          -  Age above 35 years and below 80 years

          -  Informed and written consent

          -  BMI &gt; 23 kg/m2 and &lt;35 kg/m2

        Patients with type 2 diabetes

          -  Type 2 diabetes for at least 3 months

          -  Diagnosed according to the criteria of the World Health Organization (WHO)

        Healthy Subjects

          -  Normal fasting plasma glucose (FPG) &lt;6.5 mM and

          -  Normal glycated haemoglobin (HbA1c) &lt;6.0 %

        Exclusion Criteria:

        Both groups

          -  Liver disease (alanine aminotransferase (ALAT) and/or serum aspartate
             aminotransferase (ASAT) &gt;2 times normal values) or history of hepatobiliary disorder

          -  Gastrointestinal disease, previous intestinal resection, cholecystectomy or any major
             intra-abdominal surgery

          -  Hypo- or hyperphosphataemia

          -  Nephropathy (serum creatinine &gt;150 ÂµM and/or albuminuria

          -  Treatment with medicine that cannot be paused for 12 hours

          -  Intake of antibiotics six months prior to study

          -  Hypo- or hypercalcaemia

          -  Hypo- and hyperthyroidism

          -  Treatment with oral anticoagulants

          -  Active or recent malignant disease

          -  Any treatment or condition requiring acute or sub-acute medical or surgical
             intervention

          -  Lack of effective birth control in premenopausal women

          -  Positive pregnancy test on study days in premenopausal women

          -  Tobacco smoking

          -  Any condition considered incompatible with participation by the investigators

        Patients with type 2 diabetes

          -  Treatment with insulin

          -  Treatment with incretin-based therapy

        Healthy Subjects

          -  Diabetes or

          -  prediabetes (fasting plasma glucose levels &gt;6.5 mM or HbA1c &gt;6.0%)

          -  First-degree relatives with diabetes
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andreas BrÃ¸nden, MD</last_name>
    <phone>+45 39773432</phone>
    <email>andreasbroenden@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Diabetes Research Division, Gentofte Hospital, Copenhagen</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas BrÃ¸nden, MD</last_name>
      <phone>+45 39773432</phone>
      <email>andreasbroenden@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andreas BrÃ¸nden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 10, 2014</lastchanged_date>
  <firstreceived_date>February 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Andreas BrÃ¸nden</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
